Folate-functionalized chitosan nanocarriers of an iron nitrosyl nitric oxide donor for dual antileukemic and antibacterial activity in acute myeloid leukemia cells
Acute myeloid leukemia (AML) treatment is frequently complicated by severe bacterial infections resulting from chemotherapy-induced neutropenia, creating a need for therapeutic platforms that address both leukemic progression and infection-related complications. In this study, folate-functionalized chitosan nanocarriers loaded with an iron nitrosyl nitric oxide donor, FA-CS@FeNOTSP, were developed as a dual-action platform for antileukemic and antibacterial evaluation. The nanocarriers were obtained by carbodiimide-mediated folate conjugation followed by FeNOTSP encapsulation and characterized by FT-IR, UV–Vis spectroscopy, zeta-potential analysis, scanning electron microscopy, and dynamic light scattering. FA-CS@FeNOTSP exhibited high encapsulation efficiency (approximately 85–92%), SEM-derived particle dimensions of approximately 210 nm, hydrodynamic diameters of approximately 250–327 nm in aqueous suspension, and a marked surface-charge shift consistent with folate functionalization. The formulation showed pH/GSH-responsive release, with limited FeNOTSP liberation under physiological conditions (approximately 20% at pH 7.4 after 24 h) and enhanced release under acidic, reductive conditions (approximately 40% at pH 4.5 with 10 mM GSH). DNA-binding and stopped-flow studies indicated moderate ctDNA interaction (K b = 4.31 × 10 4 M − 1 ) through a reversible two-step mechanism involving rapid electrostatic association followed by slower structural binding. FA-CS@FeNOTSP displayed low hemolytic activity (< 1%), reduced cytotoxicity toward WI38 fibroblasts (IC 50 =162.07 ± 1.89 µg mL − 1 ), retained activity against Kasumi-1 AML cells (IC 50 = 84.99 ± 1.11 µg mL − 1 ), and exerted broad-spectrum antibacterial effects (21–32 mm inhibition zones, comparable to gentamicin). Pre-exposure of Kasumi-1 cells to excess free folic acid increased the IC 50 of FA-CS@FeNOTSP by 35.4%, providing preliminary functional support for the contribution of folate-sensitive cellular interactions to the in-vitro response. Collectively, these findings support FA-CS@FeNOTSP as an in-vitro proof-of-concept multifunctional platform with responsive release, antileukemic activity, and antibacterial effects.
Authors
- Shaban Y. Shaban (ORCID: https://orcid.org/0000-0003-3717-6803)
- Fawzya I. Elshami (ORCID: https://orcid.org/0000-0002-6360-3322)
- Dalia M. Dowidar
- Ibrahim M. Elmehasseb
Institutions
- Kafrelsheikh University (EG)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1038/s41598-026-75606-w
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Science and Technology Development Fund